<DOC>
	<DOCNO>NCT00917163</DOCNO>
	<brief_summary>The objective Series III Run-In Trial compare performance efficacy Supralimus® sirolimus-eluting stent Xience V™ everolimus-eluting stent respect in-stent luminal late loss 9 month assess off-line QCA . Ninety percent power reject null hypothesis Supralimus® stent inferior Xience V™ favor alternative hypothesis Supralimus® stent inferior Xience V™ .</brief_summary>
	<brief_title>SERIES III RUN-IN Clinical Trial : A Comparison Supralimus® Stent With Xience V™ Stent</brief_title>
	<detailed_description>Series III Run-In prospective , multi-center , randomize , single-blind ( patient-blind ) , non-inferiority trial conduct approx . 35 interventional cardiology center India , Brazil , Argentina , Thailand Saudi Aurabia . A total 360 randomize 2:1 basis either Supralimus® ( sirolimus-eluting ) stent Xience V™ ( everolimus-eluting ) stent . In select site , IVUS also record patient ( maximum 60 IVUS patient total ) , baseline ( post-procedure ) 9-month follow-up . All patient follow clinically 5 year stent implantation . Repeat angiography perform patient 9 month index procedure .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<mesh_term>Everolimus</mesh_term>
	<mesh_term>Sirolimus</mesh_term>
	<criteria>Inclusion criterion : 1 . Age ≥18 year . 2 . Eligible percutaneous coronary intervention ( PCI ) 3 . Acceptable candidate CABG 4 . Clinical evidence ischemic heart disease and/or positive territorial functional study . Documented stable angina pectoris ( ( Canadian Cardiovascular Society ( CCS ) Classification 1 , 2 , 3 4 ) unstable angina pectoris document ischemia ( Braunwald Class IBC , IIBC IIIBC ) , document silent ischemia . 5 . The target lesion single de novo coronary artery lesion ≥ 50 % &lt; 100 % stenosis one major epicardial territory ( LAD , LCX RCA ) . A second target lesion another major epicardial vessel could treat second lesion fit inclusion/exclusion criterion receive type stent . 6 . The target lesion must cover one study stent , preferably margin 3 mm side lesion . 7 . The target lesion must ≤ 22 mm length visual estimate . 8 . The target reference vessel diameter must ≥ 2.5 mm ≤ 3.5 mm . 9 . Patient patient 's legal representative inform nature study agree provision provide write informed consent approve Institutional Review Board/Ethics Committee clinical site . 1 . Female childbearing potential 2 . Documented leave ventricular ejection fraction ( LVEF ) ≤ 30 % 3 . Evidence acute Qwave nonQwave myocardial infarction within 72 hour precede index procedure 4 . Known allergy follow : aspirin , clopidogrel bisulfate ( Plavix® , Ceruvin ) ticlopidine ( Ticlid® ) , heparin , sirolimus , everolimus , stainless steel , cobalt , chromium , contrast agent ( adequately premedicated ) 5 . A platelet count &lt; 100,000 cells/mm3 &gt; 700,000 cells/mm3 WBC &lt; 3,000 cells/mm3 6 . Acute chronic renal dysfunction ( creatinine &gt; 2.0mg/dl &gt; 150µmol/L ) 7 . Total occlusion ( TIMI 0 ) TIMI 1 8 . Target vessel evidence thrombus 9 . Target vessel excessively tortuous make unsuitable proper stent delivery deployment 10 . Previous bare metal stenting ( less 1 year ) anywhere within target vessel 11 . Previous drugeluting stenting anywhere within epicardial vessel 12 . The target lesion require treatment device PTCA prior stent placement ( e.g . limited , directional coronary atherectomy , excimer laser , rotational atherectomy , etc . ) 13 . Significant ( &gt; 50 % ) stenosis proximal distal target lesion might require revascularization impede runoff 14 . Heavily calcified lesion and/or calcify lesion successfully predilated 15 . Target lesion locate supply arterial venous bypass graft 16 . Ostial target lesion 17 . Target lesion involves side branch &gt; 2.0mm diameter ostial disease 18 . Patient currently participate investigational drug device study , include followup period 19 . Within 30 day prior procedure , patient undergone previous coronary interventional procedure kind 20 . Within 60 day postprocedure , patient require planned interventional treatment nontarget vessel . Planned intervention target vessel index procedure allow . 21 . Stroke transient ischemic attack within prior 6 month 22 . Unprotected Left Main ( LM ) coronary artery disease ( stenosis &gt; 50 % ) 23 . In investigator 's opinion , patient comorbid condition ( ) could limit patient 's ability participate study , compliance followup requirement impact scientific integrity study 24 . Planned surgery within 6 month index procedure 25 . Life expectancy less 1 year</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2012</verification_date>
	<keyword>coronary artery disease</keyword>
	<keyword>restenosis</keyword>
	<keyword>stent thrombosis</keyword>
	<keyword>coronary stent</keyword>
	<keyword>angioplasty</keyword>
	<keyword>drug elute stent</keyword>
</DOC>